neoadjuvant treatment breast cancer

Release time ：Dec-20,2024

Neoadjuvant therapy is a strategic approach in the management of breast cancer, designed to enhance surgical outcomes and patient survival by administering chemotherapy, radiation therapy, or targeted therapies prior to surgery, thereby reducing tumor size. This method is typically indicated for patients with large tumors, lymph node involvement, or those presenting with high-risk features.

Chemotherapy stands out as the predominant modality within neoadjuvant therapy, employing one or more anticancer medications to eradicate cancer cells. The selection and scheduling of chemotherapy drugs are contingent upon the tumor’s characteristics, stage, and the patient’s overall health. For patients with hormone receptor-positive breast cancer, endocrine therapy may be incorporated into the neoadjuvant regimen. Similarly, for those with HER2-positive breast cancer, HER2-targeted therapies may be utilized.

Patients receiving neoadjuvant therapy must be vigilant in monitoring treatment responses and side effects. Common adverse effects during treatment may include nausea, vomiting, alopecia, and fatigue. It is imperative that patients adhere to a physician’s guidance, adjust treatment plans as prescribed, and promptly communicate any symptoms of discomfort.

In conclusion, neoadjuvant therapy is instrumental in breast cancer treatment, aiding in tumor reduction and surgical success, which in turn can lead to improved patient outcomes. However, it is crucial for patients to diligently monitor their treatment responses and side effects under medical supervision to ensure the safe and effective completion of the therapeutic process.